Latin America Oral Anti-Diabetic Drug Market Size (2024 - 2029)

The Latin America Oral Anti-Diabetic Drug Market is experiencing growth, driven by the region's high prevalence of diabetes, particularly Type-2 diabetes, which is exacerbated by rising obesity rates and genetic factors. The market's expansion is influenced by the demand for oral medications, which hold a significant portion of the market share due to their necessity for a large number of individuals with diabetes in the region. The COVID-19 pandemic tested the responsiveness of health systems in Latin America, impacting the management of diabetes care.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research Latin America Oral Anti-Diabetic Drug Market Market Size

Market Size of Latin America Oral Anti-Diabetic Drug Industry

Latin America Oral Anti-Diabetic Drug Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 3.25 Billion
Market Size (2029) USD 3.86 Billion
CAGR (2024 - 2029) 3.50 %

Major Players

Latin America Oral Anti-Diabetic Drug Market Major Players

*Disclaimer: Major Players sorted in no particular order

Latin America Oral Anti-Diabetic Drug Market Analysis

The Latin America Oral Anti-Diabetic Drug Market size is estimated at USD 3.25 billion in 2024, and is expected to reach USD 3.86 billion by 2029, growing at a CAGR of 3.5% during the forecast period (2024-2029).

The ability to react to and adapt to populations, governments, and health systems around the world was put to the test by the COVID-19 pandemic. Brazil reported the first suspected and confirmed cases in Latin America on January 27 and February 26, respectively. The majority of Latin American nations failed to take prompt action to protect people with diabetes, which may have had a negative impact on people, health systems, and the economy. The ability to react to and adapt to populations, governments, and health systems around the world has been put to the test by the COVID-19 pandemic. 

Brazil presented the first suspected and first confirmed case in Latin America. The majority of Latin American nations failed to take prompt action to protect people with diabetes, which had a negative impact on people, health systems, and the economy.

Latin American nations have a high prevalence of diabetes, and Mexico is well known for having a sizable diabetic population as a result of the region's rising Type-2 diabetes prevalence. Over the past 40 years, the prevalence of Type-2 diabetes has increased, in large part due to the steadily rising obesity incidence and genetic vulnerability to the disease. Around 10% of the population currently has diabetes. About 90% of all diabetics worldwide will have Type-2 diabetes, which is the most common type in the Latin American region.

Depending on medications, the oral-drugs sector commands a substantial market share. Oral drugs are required by more than 100 million individuals in Latin America, including all of those with Type-1 diabetes and 10% to 25% of those with Type-2 diabetes. Due to the complexity of insulin production, there aren't many businesses on the market that produce it. Because of this, there is intense competition among these makers, who always work to satisfy the needs of the patient by supplying the highest-quality Oral-Anti Diabetes Drugs.

Latin America Oral Anti-Diabetic Drug Industry Segmentation

Antihyperglycemic medications are taken orally to lower blood glucose levels. They are frequently employed in the management of type 2 diabetes. The Latin America Oral Anti-Diabetic Drug Market is segmented into drugs, and Geography. The report offers the value (in USD) and volume (in Units) for the above segments.

Oral Anti-diabetic drugs
Biguanides
Alpha-Glucosidase Inhibitors
Dopamine D2 Receptor Agonist
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Meglitinides
Geography
Brazil
Mexico
Rest of Latin America
Need A Different Region Or Segment?
Customize Now

Latin America Oral Anti-Diabetic Drug Market Size Summary

The Latin America oral anti-diabetic drug market is poised for growth, driven by the region's high prevalence of Type-2 diabetes, particularly in Mexico, where obesity and genetic factors contribute to the rising incidence. The market is characterized by a significant demand for oral medications, which are essential for a substantial portion of the diabetic population, including those with Type-1 and a significant percentage of Type-2 diabetes. Despite the challenges posed by the COVID-19 pandemic, which highlighted the inadequacies in protecting diabetic individuals, the market continues to expand due to increased awareness of diabetes management and the development of innovative drugs by major pharmaceutical companies. The Brazilian health system, with its initiatives to enhance access to essential medications, plays a crucial role in this growth, alongside partnerships with private organizations to meet healthcare needs.

The market landscape is consolidated, with major global players like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals leading the charge, while other manufacturers focus on local and regional markets. The introduction of new therapies, such as Oramed's oral insulin capsule and GLP-1 analog, signifies a potential shift in diabetes treatment paradigms, offering more convenient and safer options for patients. Despite the financial constraints in diabetes care, with households covering a significant portion of direct costs, the market is expected to grow steadily, supported by improved healthcare coverage and community outreach efforts in countries like Brazil, Argentina, Colombia, and Mexico.

Explore More

Latin America Oral Anti-Diabetic Drug Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Oral Anti-diabetic drugs

      1. 2.1.1 Biguanides

      2. 2.1.2 Alpha-Glucosidase Inhibitors

      3. 2.1.3 Dopamine D2 Receptor Agonist

      4. 2.1.4 SGLT-2 inhibitors

        1. 2.1.4.1 Invokana (Canagliflozin)

        2. 2.1.4.2 Jardiance (Empagliflozin)

        3. 2.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.4.4 Suglat (Ipragliflozin)

      5. 2.1.5 DPP-4 inhibitors

        1. 2.1.5.1 Onglyza (Saxagliptin)

        2. 2.1.5.2 Tradjenta (Linagliptin)

        3. 2.1.5.3 Vipidia/Nesina(Alogliptin)

        4. 2.1.5.4 Galvus (Vildagliptin)

      6. 2.1.6 Sulfonylureas

      7. 2.1.7 Meglitinides

    2. 2.2 Geography

      1. 2.2.1 Brazil

      2. 2.2.2 Mexico

      3. 2.2.3 Rest of Latin America

Latin America Oral Anti-Diabetic Drug Market Size FAQs

The Latin America Oral Anti-Diabetic Drug Market size is expected to reach USD 3.25 billion in 2024 and grow at a CAGR of 3.5% to reach USD 3.86 billion by 2029.

In 2024, the Latin America Oral Anti-Diabetic Drug Market size is expected to reach USD 3.25 billion.

Latin America Oral Anti-Diabetic Drug Market Report Snapshots

Latin America Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)